US20020010412A1 - Multiple mechanical microporation of skin or mucosa - Google Patents

Multiple mechanical microporation of skin or mucosa Download PDF

Info

Publication number
US20020010412A1
US20020010412A1 US09/852,935 US85293501A US2002010412A1 US 20020010412 A1 US20020010412 A1 US 20020010412A1 US 85293501 A US85293501 A US 85293501A US 2002010412 A1 US2002010412 A1 US 2002010412A1
Authority
US
United States
Prior art keywords
base
puncturing
mucosa
skin
holes
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
US09/852,935
Inventor
Jonathan Eppstein
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Altea Therapeutics Corp
Spectrx Inc
Original Assignee
Spectrx Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Spectrx Inc filed Critical Spectrx Inc
Priority to US09/852,935 priority Critical patent/US20020010412A1/en
Publication of US20020010412A1 publication Critical patent/US20020010412A1/en
Assigned to ALTEA THERAPEUTICS CORPORATION reassignment ALTEA THERAPEUTICS CORPORATION CHANGE OF NAME (SEE DOCUMENT FOR DETAILS). Assignors: ALTEA DEVELOPMENT CORP.
Assigned to ALTEA DEVELOPMENT CORP. reassignment ALTEA DEVELOPMENT CORP. ASSIGNMENT OF ASSIGNORS INTEREST (SEE DOCUMENT FOR DETAILS). Assignors: ALTEA TECHNOLOGIES, INC.
Assigned to ALTEA DEVELOPMENT CORP. reassignment ALTEA DEVELOPMENT CORP. ASSIGNMENT OF ASSIGNORS INTEREST (SEE DOCUMENT FOR DETAILS). Assignors: ALTEA TECHNOLOGIES, INC.
Assigned to ALTEA THERAPEUTICS CORPORATION reassignment ALTEA THERAPEUTICS CORPORATION CHANGE OF NAME (SEE DOCUMENT FOR DETAILS). Assignors: ALTEA DEVELOPMENT CORP.
Assigned to ALTEA DEVELOPMENT CORP. reassignment ALTEA DEVELOPMENT CORP. CHANGE OF NAME (SEE DOCUMENT FOR DETAILS). Assignors: ALTEA TECHNOLOGIES, INC.
Abandoned legal-status Critical Current

Links

Images

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61MDEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M37/00Other apparatus for introducing media into the body; Percutany, i.e. introducing medicines into the body by diffusion through the skin
    • A61M37/0015Other apparatus for introducing media into the body; Percutany, i.e. introducing medicines into the body by diffusion through the skin by using microneedles
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61BDIAGNOSIS; SURGERY; IDENTIFICATION
    • A61B5/00Measuring for diagnostic purposes; Identification of persons
    • A61B5/145Measuring characteristics of blood in vivo, e.g. gas concentration, pH value; Measuring characteristics of body fluids or tissues, e.g. interstitial fluid, cerebral tissue
    • A61B5/14507Measuring characteristics of blood in vivo, e.g. gas concentration, pH value; Measuring characteristics of body fluids or tissues, e.g. interstitial fluid, cerebral tissue specially adapted for measuring characteristics of body fluids other than blood
    • A61B5/1451Measuring characteristics of blood in vivo, e.g. gas concentration, pH value; Measuring characteristics of body fluids or tissues, e.g. interstitial fluid, cerebral tissue specially adapted for measuring characteristics of body fluids other than blood for interstitial fluid
    • A61B5/14514Measuring characteristics of blood in vivo, e.g. gas concentration, pH value; Measuring characteristics of body fluids or tissues, e.g. interstitial fluid, cerebral tissue specially adapted for measuring characteristics of body fluids other than blood for interstitial fluid using means for aiding extraction of interstitial fluid, e.g. microneedles or suction
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61MDEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M37/00Other apparatus for introducing media into the body; Percutany, i.e. introducing medicines into the body by diffusion through the skin
    • A61M37/0092Other apparatus for introducing media into the body; Percutany, i.e. introducing medicines into the body by diffusion through the skin using ultrasonic, sonic or infrasonic vibrations, e.g. phonophoresis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61MDEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M37/00Other apparatus for introducing media into the body; Percutany, i.e. introducing medicines into the body by diffusion through the skin
    • A61M2037/0007Other apparatus for introducing media into the body; Percutany, i.e. introducing medicines into the body by diffusion through the skin having means for enhancing the permeation of substances through the epidermis, e.g. using suction or depression, electric or magnetic fields, sound waves or chemical agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61MDEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M37/00Other apparatus for introducing media into the body; Percutany, i.e. introducing medicines into the body by diffusion through the skin
    • A61M37/0015Other apparatus for introducing media into the body; Percutany, i.e. introducing medicines into the body by diffusion through the skin by using microneedles
    • A61M2037/0023Drug applicators using microneedles
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61MDEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M37/00Other apparatus for introducing media into the body; Percutany, i.e. introducing medicines into the body by diffusion through the skin
    • A61M37/0015Other apparatus for introducing media into the body; Percutany, i.e. introducing medicines into the body by diffusion through the skin by using microneedles
    • A61M2037/0038Other apparatus for introducing media into the body; Percutany, i.e. introducing medicines into the body by diffusion through the skin by using microneedles having a channel at the side surface
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61MDEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M37/00Other apparatus for introducing media into the body; Percutany, i.e. introducing medicines into the body by diffusion through the skin
    • A61M37/0015Other apparatus for introducing media into the body; Percutany, i.e. introducing medicines into the body by diffusion through the skin by using microneedles
    • A61M2037/0053Methods for producing microneedles

Definitions

  • This invention relates to a device and method for puncturing a selected layer or layers of the skin or mucosa. More particularly, the invention relates a device and method for puncturing the stratum corneum or mucosa to diminish the barrier function thereof and permit a drug to be delivered to the body or an analyte in the body to be withdrawn for monitoring.
  • This puncturing of the stratum corneum or mucosa is minimally is invasive, and can be combined with various other methods, such as use of chemical enhancers, pressure gradients, sonic gradients, temperature gradients, and the like for selectively enhancing the inward flux of a drug to the body or the outward flux of an analyte from the body.
  • the stratum corneum is chiefly responsible for the well-known barrier properties of skin. Thus, it is this layer of the skin that presents the greatest barrier to transdermal flux of drugs or other molecules into the body and of analytes out of the body. Mucosal tissue also presents a barrier to flux of molecules into and out of the body.
  • the stratum corneum, the outer horny layer of the skin, is a complex structure of compact keratinized cell remnants separated by lipid domains. Compared to the oral or gastric mucosa, the stratum corneum is much less permeable to molecules either external or internal to the body.
  • U.S. Pat. No. 5,458,140 and U.S. Pat. No. 5,445,611 disclose using ultrasonic energy that is modulated in intensity, phase, or frequency or a combination thereof.
  • U.S. Pat. No. 4,775,361 discloses a method of administering a drug by ablating the stratum corneum using pulsed laser light without significantly damaging the underlying epidermis.
  • Numerous patents teach the use of chemical enhancers for improving transdermal flux of a drug through the skin. E.g., U.S. Pat. No. 4,863,970. It would be advantageous to develop additional methods of permeating the stratum corneum or mucosa to enhance the transport of drugs into the body or analytes out of the body, particularly without the need for expensive or complicated equipment.
  • the device is fabricated by microlithography and is composed of a material selected from the group consisting of silicon, metal, and plastic. It is also preferred that the puncturing member be in the shape of a pyramid or wedge. The pyramid or wedge preferably have sharp edges having corner radii of less than 1 ⁇ m.
  • the puncturing member is preferably configured for puncturing the skin or mucosa to a depth of about 30-50 ⁇ m, and a dimension at a base thereof is preferably about 10-50 ⁇ m.
  • the puncturing members preferably occupy up to about 50% of the surface area of the lower surface of the base.
  • the device preferably further comprises a mechanism for producing vibrations, the vibrations for facilitating efficient and non-traumatic penetration of the puncturing members into the skin or mucosa.
  • a preferred vibration-producing mechanism comprises a piezo-electric transducer. It is preferred that the mechanism for producing vibrations produces vibrations in the range of about 2000 Hz to about 100 MHz.
  • an external reservoir for holding a liquid drug composition to be delivered to the body is provided.
  • a mechanism for limiting the rate of drug delivery is preferably included in the device, the mechanism positioned between the external reservoir and the puncturing members.
  • rate-limiting mechanisms can include selective permeability membranes and valve mechanisms.
  • the device is disposable.
  • a method for reducing the barrier function of skin or mucosa to the delivery of substances into a body or withdrawal of analytes out of the body comprises:
  • a base having a lower side and an upper side
  • a plurality of puncturing members extending from the lower side of the base, the puncturing members configured for puncturing the skin or mucosa to a depth sufficient to reduce the barrier properties thereof without significantly damaging underlying tissues;
  • a plurality of holes extending from the lower side of the base to the upper side of the base, the holes configured for permitting a liquid to move therethrough by capillary action;
  • a network of channels configured in the upper side of the base to interconnect the holes
  • a method of transdermal or transmucosal monitoring of a selected analyte in a body comprises:
  • a base having a lower side and an upper side
  • a plurality of puncturing members extending from the lower side of the base, the puncturing members configured for puncturing said skin or mucosa to a depth sufficient to reduce the barrier properties thereof without significantly damaging underlying tissues;
  • a plurality of holes extending from the lower side of the base to the upper side of the base, the holes configured for permitting a liquid to move therethrough by capillary action;
  • a network of channels configured in the upper side of the base to interconnect the holes, the network of channels including a reservoir;
  • the method further comprises applying suction to increase the rate of collection of interstitial fluid.
  • Ultrasonic vibrations can also be applied to the skin or mucosa to increase the rate of collection of the selected analyte.
  • the ultrasonic vibrations can be modulated in frequency, intensity, phase, or a combination thereof, as disclosed in U.S. Pat. No. 5,458,140, hereby incorporated by reference.
  • the ultrasonic vibrations are preferably in the range of about 2000 Hz to about 100 MHz.
  • the ultrasonic vibrations can also enhance the movement of interstitial fluid by capillary action.
  • the selected analyte is glucose. It is also preferred to apply an anticoagulant to inhibit obstruction of the holes or channels.
  • a method of transdermally or transmucosally delivering a drug in liquid form to a body comprises:
  • a base having a lower side and an upper side
  • a plurality of puncturing members extending from the lower side of the base, the puncturing members configured for puncturing the skin or mucosa to a depth sufficient to reduce the barrier properties thereof without significantly damaging underlying tissues;
  • a plurality of holes extending from the lower side of the base to the upper side of the base, the holes configured for permitting a liquid to move therethrough by capillary action;
  • a network of channels configured in the upper side of the base to interconnect the holes, the network of channels including a reservoir;
  • pressure is applied to increase the rate of delivery of the drug to the body.
  • Applying ultrasonic vibrations to the skin or mucosa also increases the rate of delivery of the drug to the body.
  • the ultrasonic vibrations can be modulated in frequency, intensity, phase, or a combination thereof, as disclosed in U.S. Pat. No. 5,445,611, hereby incorporated by reference.
  • the ultrasonic vibrations are preferably in the range of about 2000 Hz to about 100 MHz.
  • the drug in liquid form can further comprise an anti-irritant, antiseptic, or analgesic to reduce trauma to the body due to the application of the device.
  • FIG. 1 shows a perspective view of an illustrative embodiment of the present invention.
  • FIG. 2 shows a cross section of a portion of another illustrative embodiment according to the present invention.
  • FIG. 3 shows a perspective view of a portion of the embodiment of FIG. 2.
  • FIG. 5 shows a schematic diagram of a device for making multiple microporations in skin or mucosa and collecting interstitial fluid.
  • FIG. 6 shows a schematic sectional diagram of a device for making multiple microporations in skin or mucosa and delivering a drug.
  • One illustrative method would be to utilize the existing base of manufacturing capabilities developed in the semiconductor and micro-mechanical industries to dry-etch an entire 4 inch silicon wafer with a network of these devices. This master could then be used as the basis for an electroplated mold from which thousands of copies could be produced. For a typical useable surface area/per device application of 4 mm ⁇ 4 mm, one 4-inch wafer would yield more than 500 of the devices.
  • a device according to the present invention is made, for example, by first preparing a master by a dry etch process on a silicon wafer, as is well known in the art. Photolithographical processes for etching micrometer-scale structures into silicon waters and the like are described in A. T. Wooley & R. A. Mathies, Ultra-high-speed DNA fragment separations using microfabricated capillary array electrophoresis chips, 91 Biophysics 11348-52 (1994); C. S. Effenhauser et al., High-speed separation of antisense oligonucleotides on a micromachined capillary electrophoresis device, 66 Anal. Chem. 2949 (1994); C.
  • ultrasound has been shown to enhance the smooth cutting ability of scalpels and other surgical devices and can be expected to facilitate the easy, painless penetration of the puncturing elements into the stratum corneum with very little pressure.
  • the edges of the pyramidally shaped puncturing elements shown in FIG. 1 can easily be fabricated such that the corner radius is less than 10 nanometers, a sharpness similar to a surgical scalpel.
  • ultrasound has also been shown to greatly enhance capillary action, thus the amount of fluid that could be collected in a device containing a capillary collection system could be expected to be significantly greater than that provided by mere passive means.
  • FIG. 1 shows a perspective view of an illustrative device according to the present invention.
  • the device 10 comprises a base 14 with a plurality of puncturing members 18 extending therefrom.
  • the base is substantially planar.
  • Each puncturing member comprises a sharp point 22 or edge for puncturing the stratum corneum or mucosa. Since the stratum corneum can be up to about 30 ⁇ m thick, it is preferred that the puncturing element have a height of about 40-50 ⁇ m to ensure that the stratum corneum will be fully breached without significantly damaging the underlying tissue.
  • a pyramid or wedge shape is a preferred shape for the puncturing member because of the ease with which such a shape can be formed by microfabrication techniques such as microlithography.
  • the base of the pyramid would preferably have a square base about 30-40 ⁇ m on a side.
  • the base have a plurality of holes 26 extending therethrough from the lower side 30 , on which the puncturing element are disposed, to the upper side 34 .
  • each puncturing element is adjacent to and paired with at least one hole for collecting the interstitial fluid that seeps out of the puncture in the stratum corneum.
  • These holes should be dimensioned to permit the interstitial fluid to move by capillary action from the lower side of the device to the upper side, where the interstitial fluid can be collected.
  • FIGS. 2,3, and 4 shows how the V-grooves 70 interconnect the V-channels for collecting the interstitial fluid. All of the puncturing members, channels, and grooves shown in FIGS. 2,3, and 4 are designed to be wedge-shaped, compatible with being produced in the crystalline structure of a silicon substrate with a lithographic ‘dry-etch’ type of process.
  • FIG. 5 shows an illustrative device 80 for collecting interstitial fluid according to the present invention.
  • the device 80 comprises a base 84 having a plurality of puncturing members 88 extending therefrom.
  • V-shaped channels and grooves are configured into the upper side 92 of the base for collecting the interstitial fluid.
  • a cover plate 96 fits over the base to cover the network of channels and grooves and to inhibit evaporation of the interstitial fluid.
  • the network of channels and grooves leads the interstitial fluid to a central area, where there is disposed a capillary tube 100 for receiving the interstitial fluid.
  • Atop the cover plate is disposed an ultrasonic transducer 104 and a backing 108 for the tranducer.
  • the device is pressed against a selected area of skin or mucosa, and the ultrasonic transducer is activated to aid in both the puncturing of the tissue and in enhancing the seepage of the interstitial fluid.
  • the interstitial fluid is collected by the network of openings in the base, and is conducted by the network of channels and grooves to the capillary, which takes up the fluid by capillary action.
  • the fluid is then analyzed according to methods known in the art.
  • An illustrative analyte is glucose, which can be quantified with various test strips that are available commercially.
  • FIG. 6 shows an illustrative drug delivery device 120 comprising a base 124 having a plurality of puncturing members 128 extending therefrom.
  • a network of grooves and channels (see FIGS. 2 - 4 ) is embedded in the base for distributing a drug composition 132 from a reservoir 136 .
  • the reservoir is bounded by a housing 138 , the base, and a backing plate 144 including an O-ring 148 .
  • the drug composition flows through the channels, grooves, and openings in the base to the surface of the skin or mucosa for entry into the body through the punctures or perforations.
  • An ultrasound transducer 140 lies over the drug composition for aiding in delivery thereof. Above the transducer is the backing plate 144 including the O-ring for sealing the drug in the reservoir.
  • a spring 152 can advantageously bias the backing plate against the transducer, which causes the transducer to be kept in fluid contact with the drug.
  • the ultrasonic system is utilized not only to enhance the slicing action of the edges of the puncturing elements as the penetrate into the stratum corneum or mucosa, but is then utilized to enhance the fluid flux of the therapeutic containing solution through the micro-pores and into the underlying tissues.
  • large quantities of large molecular weight drugs could be delivered transdermally with a programmable control of the flux rate via variable activation of the ultrasonic pumping system.
  • the sonic energy can be utilized to create controlled resonant vibrations in specifically shaped micro-structures such that a micro-pump is created to facilitate driving the collected fluid from one point to another within the entire structure.
  • chemical enhancers, air pressure, and other methods known in the art can be used to enhance the passage of the drug through the micropores in the skin or mucosa into the body.

Abstract

A device and methods of use for delivering a drug to the body, or monitoring an analyte found in the body, are described. The device includes a base, a plurality of puncturing members extending from the base, a plurality of holes extending through the base for the passage of the drug or the analyte, and a network of channels for distributing the drug or collecting the analyte. Methods of trans-dermal or trans-mucous delivery of a drug or monitoring of an analyte are also described.

Description

    CROSS REFERENCE TO RELATED APPLICATIONS
  • This application claims the benefit of U.S. Provisional Application No. 60/021,212, filed Jul. 3, 1996.[0001]
  • BACKGROUND OF THE INVENTION
  • This invention relates to a device and method for puncturing a selected layer or layers of the skin or mucosa. More particularly, the invention relates a device and method for puncturing the stratum corneum or mucosa to diminish the barrier function thereof and permit a drug to be delivered to the body or an analyte in the body to be withdrawn for monitoring. This puncturing of the stratum corneum or mucosa is minimally is invasive, and can be combined with various other methods, such as use of chemical enhancers, pressure gradients, sonic gradients, temperature gradients, and the like for selectively enhancing the inward flux of a drug to the body or the outward flux of an analyte from the body. [0002]
  • The stratum corneum is chiefly responsible for the well-known barrier properties of skin. Thus, it is this layer of the skin that presents the greatest barrier to transdermal flux of drugs or other molecules into the body and of analytes out of the body. Mucosal tissue also presents a barrier to flux of molecules into and out of the body. The stratum corneum, the outer horny layer of the skin, is a complex structure of compact keratinized cell remnants separated by lipid domains. Compared to the oral or gastric mucosa, the stratum corneum is much less permeable to molecules either external or internal to the body. The stratum corneum is formed from keratinocytes, which comprise the majority of the epidermal cells, that lose their nuclei and become corneocytes. These dead cells comprise the stratum corneum, which has a thickness of about 10-30 μm and, as noted above, is a very resistant waterproof membrane that protects the body from invasion by exterior substances and the outward migration of fluids and dissolved molecules. The stratum corneum is continuously renewed by shedding of corneum cells during desquamination and the formation of new corneum cells by the keratinization process. [0003]
  • Various methods of enhancing the permeability of the stratum corneum and mucosa have been described. For example, U.S. Pat. No. 5,458,140 and U.S. Pat. No. 5,445,611 disclose using ultrasonic energy that is modulated in intensity, phase, or frequency or a combination thereof. U.S. Pat. No. 4,775,361 discloses a method of administering a drug by ablating the stratum corneum using pulsed laser light without significantly damaging the underlying epidermis. Numerous patents teach the use of chemical enhancers for improving transdermal flux of a drug through the skin. E.g., U.S. Pat. No. 4,863,970. It would be advantageous to develop additional methods of permeating the stratum corneum or mucosa to enhance the transport of drugs into the body or analytes out of the body, particularly without the need for expensive or complicated equipment. [0004]
  • In view of the foregoing, it will be appreciated that providing a device and method of use thereof for introducing multiple micropores or perforations in the stratum corneum or mucosa for enhancing transport of molecules therethrough would be a significant advancement in the art. [0005]
  • BRIEF SUMMARY OF THE INVENTION
  • It is an object of the present invention to provide a simple, inexpensive device for puncturing the stratum corneum or mucosa without significantly damaging the underlying tissues to facilitate transport of molecules therethrough. [0006]
  • It is also an object of the invention to provide a method of enhancing the passage of molecules through the stratum corneum or mucosa. [0007]
  • It is another object of the invention to provide a method for transdermally or transmucosally delivering a drug. [0008]
  • It is still another object of the invention to provide a method for transdermally or transmucosally monitoring an analyte. [0009]
  • These and other objects can be achieved by providing a device for reducing the barrier properties of skin or mucosa to the delivery of a substance into the body or the withdrawal of an analyte from the body comprising: [0010]
  • (a) a base having a lower side and an upper side; [0011]
  • (b) a plurality of puncturing members extending from the lower side of the base, the puncturing members configured for puncturing the skin or mucosa to a depth sufficient to reduce the barrier properties thereof without significantly damaging underlying tissues; [0012]
  • (c) a plurality of holes extending from the lower side of the base to the upper side of the base, the holes configured for permitting a liquid to move therethrough by capillary action; and [0013]
  • (d) a network of channels configured in the upper side of the base to interconnect the holes. [0014]
  • Preferably, the device is fabricated by microlithography and is composed of a material selected from the group consisting of silicon, metal, and plastic. It is also preferred that the puncturing member be in the shape of a pyramid or wedge. The pyramid or wedge preferably have sharp edges having corner radii of less than 1 μm. The puncturing member is preferably configured for puncturing the skin or mucosa to a depth of about 30-50 μm, and a dimension at a base thereof is preferably about 10-50 μm. The puncturing members preferably occupy up to about 50% of the surface area of the lower surface of the base. [0015]
  • The device preferably further comprises a mechanism for producing vibrations, the vibrations for facilitating efficient and non-traumatic penetration of the puncturing members into the skin or mucosa. A preferred vibration-producing mechanism comprises a piezo-electric transducer. It is preferred that the mechanism for producing vibrations produces vibrations in the range of about 2000 Hz to about 100 MHz. [0016]
  • In another illustrative embodiment of the device, an external reservoir for holding a liquid drug composition to be delivered to the body is provided. Still further, a mechanism for limiting the rate of drug delivery is preferably included in the device, the mechanism positioned between the external reservoir and the puncturing members. Such rate-limiting mechanisms can include selective permeability membranes and valve mechanisms. In another preferred embodiment, the device is disposable. [0017]
  • A method for reducing the barrier function of skin or mucosa to the delivery of substances into a body or withdrawal of analytes out of the body, comprises: [0018]
  • (a) providing a device comprising: [0019]
  • a base having a lower side and an upper side; [0020]
  • a plurality of puncturing members extending from the lower side of the base, the puncturing members configured for puncturing the skin or mucosa to a depth sufficient to reduce the barrier properties thereof without significantly damaging underlying tissues; [0021]
  • a plurality of holes extending from the lower side of the base to the upper side of the base, the holes configured for permitting a liquid to move therethrough by capillary action; and [0022]
  • a network of channels configured in the upper side of the base to interconnect the holes; [0023]
  • (b) contacting the device with the skin or mucosa such that the plurality of puncturing members puncture the skin or mucosa to a depth sufficient to reduce the barrier properties thereof. [0024]
  • A method of transdermal or transmucosal monitoring of a selected analyte in a body comprises: [0025]
  • (a) providing a device comprising: [0026]
  • a base having a lower side and an upper side; [0027]
  • a plurality of puncturing members extending from the lower side of the base, the puncturing members configured for puncturing said skin or mucosa to a depth sufficient to reduce the barrier properties thereof without significantly damaging underlying tissues; [0028]
  • a plurality of holes extending from the lower side of the base to the upper side of the base, the holes configured for permitting a liquid to move therethrough by capillary action; and [0029]
  • a network of channels configured in the upper side of the base to interconnect the holes, the network of channels including a reservoir; [0030]
  • (b) contacting the device with the skin or mucosa such that the plurality of puncturing members puncture the skin or mucosa to a depth sufficient to reduce the barrier properties thereof resulting in seepage of interstitial fluid to the surface of the skin or mucosa such that interstitial fluid moves by capillary action through the holes, through the channels, to the reservoir; [0031]
  • (c) collecting the interstitial fluid from the reservoir; and [0032]
  • (d) analyzing the interstitial fluid with respect to the selected analyte. [0033]
  • In a preferred embodiment, the method further comprises applying suction to increase the rate of collection of interstitial fluid. Ultrasonic vibrations can also be applied to the skin or mucosa to increase the rate of collection of the selected analyte. The ultrasonic vibrations can be modulated in frequency, intensity, phase, or a combination thereof, as disclosed in U.S. Pat. No. 5,458,140, hereby incorporated by reference. The ultrasonic vibrations are preferably in the range of about 2000 Hz to about 100 MHz. The ultrasonic vibrations can also enhance the movement of interstitial fluid by capillary action. In a preferred embodiment of the invention, the selected analyte is glucose. It is also preferred to apply an anticoagulant to inhibit obstruction of the holes or channels. [0034]
  • A method of transdermally or transmucosally delivering a drug in liquid form to a body comprises: [0035]
  • (a) providing a device comprising: [0036]
  • a base having a lower side and an upper side; [0037]
  • a plurality of puncturing members extending from the lower side of the base, the puncturing members configured for puncturing the skin or mucosa to a depth sufficient to reduce the barrier properties thereof without significantly damaging underlying tissues; [0038]
  • a plurality of holes extending from the lower side of the base to the upper side of the base, the holes configured for permitting a liquid to move therethrough by capillary action; and [0039]
  • a network of channels configured in the upper side of the base to interconnect the holes, the network of channels including a reservoir; [0040]
  • (b) contacting the device with the skin or mucosa such that the plurality of puncturing members puncture the skin or mucosa to a depth sufficient to reduce the barrier properties thereof; [0041]
  • (c) supplying the drug to the reservoir such that said drug moves from the reservoir, through the channels and holes to the site of the punctures of the skin or mucosa and thus into the body. [0042]
  • In a preferred embodiment, pressure is applied to increase the rate of delivery of the drug to the body. Applying ultrasonic vibrations to the skin or mucosa also increases the rate of delivery of the drug to the body. The ultrasonic vibrations can be modulated in frequency, intensity, phase, or a combination thereof, as disclosed in U.S. Pat. No. 5,445,611, hereby incorporated by reference. The ultrasonic vibrations are preferably in the range of about 2000 Hz to about 100 MHz. The drug in liquid form can further comprise an anti-irritant, antiseptic, or analgesic to reduce trauma to the body due to the application of the device.[0043]
  • BRIEF DESCRIPTION OF THE SEVERAL VIEWS OF THE DRAWINGS
  • FIG. 1 shows a perspective view of an illustrative embodiment of the present invention. [0044]
  • FIG. 2 shows a cross section of a portion of another illustrative embodiment according to the present invention. [0045]
  • FIG. 3 shows a perspective view of a portion of the embodiment of FIG. 2. [0046]
  • FIG. 4 shows a top view of a portion of the embodiment of FIG. 2. [0047]
  • FIG. 5 shows a schematic diagram of a device for making multiple microporations in skin or mucosa and collecting interstitial fluid. [0048]
  • FIG. 6 shows a schematic sectional diagram of a device for making multiple microporations in skin or mucosa and delivering a drug.[0049]
  • DETAILED DESCRIPTION
  • Before the present device and method for enhancing permeability of skin or mucosa for drug delivery or analyte monitoring are disclosed and described, it is to be understood that this invention is not limited to the particular configurations, process steps, and materials disclosed herein as such configurations, process steps, and materials may vary somewhat. It is also to be understood that the terminology employed herein is used for the purpose of describing particular embodiments only and is not intended to be limiting since the scope of the present invention will be limited only by the appended claims and equivalents thereof. [0050]
  • It must be noted that, as used in this specification and the appended claims, the singular forms “a,” “an,” and “the” include plural referents unless the context clearly dictates otherwise. Thus, for example, reference to a device containing “a puncturing member” includes a device containing two or more of such members, reference to “a channel” includes reference to one or more of such channels, and reference to “an ultrasound transducer” includes reference to two or more ultrasound transducers. [0051]
  • It has been observed that forming a hole or micropore, 30 μm across, in the stratum corneum yields a quick source of about 0.2 microliters of interstitial fluid seeping through the hole from the underlying tissue without any additional pumping. Merely increasing the number of holes introduced through the stratum corneum would increases the amount of passively available fluid in a linear fashion. That is, creating 100 holes should produce about 20 microliters of interstitial fluid. From a practical perspective, using known approaches to create 100 holes in a controlled pattern would be challenging and time-consuming. However, using the mechanical puncturing capabilities of a mechanical microporation or “bed-of-nails” device would allow an almost unlimited number of micropores to be quickly created in any selected pattern. Similarly, using conventional lancet and needle technologies would make the needed depth control of the puncture very tricky and, if the device were to create hundreds of these holes, the mechanical challenge of building the device using conventional metal needle technologies would be formidable. However, by fabricating puncturing elements en masse such that they protrude from a substantially planar surface, with sufficient spacing between each to allow the stratum corneum to come in contact with this intervening planar surface, the absolute length of the puncturing elements themselves would act as an accurate limit for the depth of the micropore. Also, using a microlithography approach to fabricate these structures will allow an entire surface comprised of puncturing elements and the interconnecting fluid management system to be built very cost effectively. [0052]
  • One illustrative method would be to utilize the existing base of manufacturing capabilities developed in the semiconductor and micro-mechanical industries to dry-etch an entire 4 inch silicon wafer with a network of these devices. This master could then be used as the basis for an electroplated mold from which thousands of copies could be produced. For a typical useable surface area/per device application of 4 mm×4 mm, one 4-inch wafer would yield more than 500 of the devices. [0053]
  • A device according to the present invention is made, for example, by first preparing a master by a dry etch process on a silicon wafer, as is well known in the art. Photolithographical processes for etching micrometer-scale structures into silicon waters and the like are described in A. T. Wooley & R. A. Mathies, Ultra-high-speed DNA fragment separations using microfabricated capillary array electrophoresis chips, 91 Biophysics 11348-52 (1994); C. S. Effenhauser et al., High-speed separation of antisense oligonucleotides on a micromachined capillary electrophoresis device, 66 Anal. Chem. 2949 (1994); C. Effenhauser et al., 65 Anal. Chem. 2637 (1993); Z. H. Fan & D. J. Harrison, Micromachining of capillary electrophoresis injectors and separators on glass chips and evaluation of flow at capillary intersections, 66 Anal. Chem. 177-84 (1994); W. H. Ko et al., in Sensors: A Comprehensive Survey, T. Grandke, W. H. Ko, eds., VCH Press: Weinheim, Germany, Vol. 1, pp. 107-68 (1989); K. E. Petersen, 70 Proc. IEEE 420-57 (1982), which are hereby incorporated by reference. The master silicon wafer is then used to make an electroplated mold, and then the mold is used to make copies of the device, all by processes well known in the art. [0054]
  • Also, by coupling the entire device to an ultrasonic transducer, several known advantages can be realized simultaneously. For example, ultrasound has been shown to enhance the smooth cutting ability of scalpels and other surgical devices and can be expected to facilitate the easy, painless penetration of the puncturing elements into the stratum corneum with very little pressure. The edges of the pyramidally shaped puncturing elements shown in FIG. 1 can easily be fabricated such that the corner radius is less than 10 nanometers, a sharpness similar to a surgical scalpel. Second, ultrasound has also been shown to greatly enhance capillary action, thus the amount of fluid that could be collected in a device containing a capillary collection system could be expected to be significantly greater than that provided by mere passive means. Third, by using the entire body of the puncturing elements to provide a conduit for the ultrasonic energy, a simple method is presented wherein the sonic energy is placed within the body where it can provide a positive pressure, and streaming action on the interstitial fluid from within the body outward towards a collection system of capillary channels coupling all fluid harvested into a central reservoir. [0055]
  • FIG. 1 shows a perspective view of an illustrative device according to the present invention. The [0056] device 10 comprises a base 14 with a plurality of puncturing members 18 extending therefrom. In a preferred embodiment, the base is substantially planar. Each puncturing member comprises a sharp point 22 or edge for puncturing the stratum corneum or mucosa. Since the stratum corneum can be up to about 30 μm thick, it is preferred that the puncturing element have a height of about 40-50 μm to ensure that the stratum corneum will be fully breached without significantly damaging the underlying tissue. A pyramid or wedge shape is a preferred shape for the puncturing member because of the ease with which such a shape can be formed by microfabrication techniques such as microlithography. In an illustrative puncturing element having a pyramid shape, the base of the pyramid would preferably have a square base about 30-40 μm on a side.
  • It is also preferred that the base have a plurality of [0057] holes 26 extending therethrough from the lower side 30, on which the puncturing element are disposed, to the upper side 34. Preferably, each puncturing element is adjacent to and paired with at least one hole for collecting the interstitial fluid that seeps out of the puncture in the stratum corneum. These holes should be dimensioned to permit the interstitial fluid to move by capillary action from the lower side of the device to the upper side, where the interstitial fluid can be collected. It is also preferred to interconnect the holes with capillary channels 38 that are formed in the upper side of the device. Preferably, such channels intersect at a reservoir 42. The interstitial fluid moves by capillarity from the micropore into the hole, through the channels, and to the reservoir, where the interstitial fluid is collected, such as with a micropipet. Additional fluid can be collected by applying suction to the microporated area of skin or mucosa.
  • FIGS. [0058] 2-4 show another illustrative embodiment of the invention. FIG. 2 shows a cross section of a portion of the device 50 comprising a base 54 with a puncturing member 58 extending therefrom. The puncturing member is pyramid-shaped, as in FIG. 1. The upper side 62 of the base is configured with a V-shaped channel 66 positioned such that the channel is directly over the puncturing member and cuts into the volume circumscribed by the puncturing member. FIG. 3 shows a perspective view of the device having the V-shaped channels 66 and interconnecting shallower V-grooves 70. The channels 66 cut through the lower side 74 of the base, and thus form openings through which the interstitial fluid can be taken up by capillary action. FIG. 4 shows how the V-grooves 70 interconnect the V-channels for collecting the interstitial fluid. All of the puncturing members, channels, and grooves shown in FIGS. 2,3, and 4 are designed to be wedge-shaped, compatible with being produced in the crystalline structure of a silicon substrate with a lithographic ‘dry-etch’ type of process.
  • FIG. 5 shows an [0059] illustrative device 80 for collecting interstitial fluid according to the present invention. The device 80 comprises a base 84 having a plurality of puncturing members 88 extending therefrom. V-shaped channels and grooves are configured into the upper side 92 of the base for collecting the interstitial fluid. A cover plate 96 fits over the base to cover the network of channels and grooves and to inhibit evaporation of the interstitial fluid. The network of channels and grooves leads the interstitial fluid to a central area, where there is disposed a capillary tube 100 for receiving the interstitial fluid. Atop the cover plate is disposed an ultrasonic transducer 104 and a backing 108 for the tranducer.
  • The device is pressed against a selected area of skin or mucosa, and the ultrasonic transducer is activated to aid in both the puncturing of the tissue and in enhancing the seepage of the interstitial fluid. The interstitial fluid is collected by the network of openings in the base, and is conducted by the network of channels and grooves to the capillary, which takes up the fluid by capillary action. The fluid is then analyzed according to methods known in the art. An illustrative analyte is glucose, which can be quantified with various test strips that are available commercially. [0060]
  • FIG. 6 shows an illustrative [0061] drug delivery device 120 comprising a base 124 having a plurality of puncturing members 128 extending therefrom. A network of grooves and channels (see FIGS. 2-4) is embedded in the base for distributing a drug composition 132 from a reservoir 136. The reservoir is bounded by a housing 138, the base, and a backing plate 144 including an O-ring 148. The drug composition flows through the channels, grooves, and openings in the base to the surface of the skin or mucosa for entry into the body through the punctures or perforations. An ultrasound transducer 140 lies over the drug composition for aiding in delivery thereof. Above the transducer is the backing plate 144 including the O-ring for sealing the drug in the reservoir. A spring 152 can advantageously bias the backing plate against the transducer, which causes the transducer to be kept in fluid contact with the drug.
  • The ultrasonic system is utilized not only to enhance the slicing action of the edges of the puncturing elements as the penetrate into the stratum corneum or mucosa, but is then utilized to enhance the fluid flux of the therapeutic containing solution through the micro-pores and into the underlying tissues. In this case, large quantities of large molecular weight drugs could be delivered transdermally with a programmable control of the flux rate via variable activation of the ultrasonic pumping system. In addition, the sonic energy can be utilized to create controlled resonant vibrations in specifically shaped micro-structures such that a micro-pump is created to facilitate driving the collected fluid from one point to another within the entire structure. Moreover, chemical enhancers, air pressure, and other methods known in the art can be used to enhance the passage of the drug through the micropores in the skin or mucosa into the body. [0062]

Claims (48)

I claim:
1. A device for reducing the barrier properties of skin or mucosa to the delivery of a substance into the body or the withdrawal of an analyte from the body comprising:
(a) a base having a lower side and an upper side;
(b) a plurality of puncturing members extending from the lower side of the base, said puncturing members configured for puncturing said skin or mucosa to a depth sufficient to reduce the barrier properties thereof without significantly damaging underlying tissues;
(c) a plurality of holes extending from the lower side of the base to the upper side of the base, said holes configured for permitting a liquid to move therethrough by capillary action; and
(d) a network of channels configured in the upper side of said base to interconnect said holes.
2. The device of claim 1 wherein said device is fabricated by microlithography.
3. The device of claim 1 wherein said device is fabricated of a material selected from the group consisting of silicon, metal, and plastic.
4. The device of claim 1 wherein said puncturing member is in the shape of a pyramid or wedge.
5. The device of claim 4 wherein said pyramid or wedge comprises sharp edges having corner radii of less than 1 μm.
6. The device of claim 1 wherein said puncturing member is configured for puncturing said skin or mucosa to a depth of about 30-50 μm.
7. The device of claim 1 wherein said plurality of puncturing members occupy up to about 50% of the surface area of the lower surface of the base.
8. The device of claim 1 wherein said puncturing member has a dimension at a base thereof of about 10-50 μm.
9. The device of claim 1 wherein said each of said holes is positioned adjacent to a puncturing member.
10. The device of claim 1 wherein said network of channels further comprises a reservoir for holding liquid.
11. The device of claim 1 wherein said base is substantially planar.
12. The device of claim 1 further comprising a mechanism for producing vibrations, said vibrations for facilitating efficient and non-traumatic penetration of the puncturing members into the skin or mucosa.
13. The device of claim 12 wherein said mechanism for producing vibrations comprises a piezo-electric transducer.
14. The device of claim 12 wherein said mechanism for producing vibrations produces vibrations in the range of about 2000 Hz to about 100 MHz.
15. The device of claim 1 further comprising an external reservoir for holding a liquid drug composition to be delivered to the body.
16. The device of claim 15 further comprising a mechanism for limiting the rate of drug delivery, said mechanism positioned between the external reservoir and the puncturing members.
17. The device of claim 1 wherein said device is disposable.
18. A method for reducing the barrier function of skin or mucosa to the delivery of substances into a body or withdrawal of analytes out of the body, comprising:
(a) providing a device comprising:
a base having a lower side and an upper side;
a plurality of puncturing members extending from the lower side of the base, said puncturing members configured for puncturing said skin or mucosa to a depth sufficient to reduce the barrier properties thereof without significantly damaging underlying tissues;
a plurality of holes extending from the lower side of the base to the upper side of the base, said holes configured for permitting a liquid to move therethrough by capillary action; and
a network of channels configured in the upper side of said base to interconnect said holes;
(b) contacting said device with the skin or mucosa such that said plurality of puncturing members puncture the skin or mucosa to a depth sufficient to reduce the barrier properties thereof.
19. The method of claim 18 wherein said device is fabricated by microlithography.
20. The method of claim 18 wherein said device is fabricated of a material selected from the group consisting of silicon, metal, and plastic.
21. The method of claim 18 wherein said puncturing member is in the shape of a pyramid or wedge.
22. The method of claim 21 wherein said pyramid or wedge comprises sharp edges having corner radii of less than 1 μm.
23. The method of claim 18 wherein said puncturing member is configured for puncturing said skin or mucosa to a depth of about 30-50 μm.
24. The method of claim 18 wherein said plurality of puncturing members occupy up to about 50% of the surface area of the lower surface of the base.
25. The method of claim 18 wherein said puncturing member has a dimension at a base thereof of about 10-50 μm.
26. The method of claim 18 wherein said each of said holes is positioned adjacent to a puncturing member.
27. The method of claim 18 wherein said network of channels further comprises a reservoir for holding liquid.
28. The method of claim 18 wherein said base is substantially planar.
29. The method of claim 18 further comprising a mechanism for producing vibrations, said vibrations for facilitating efficient and non-traumatic penetration of the puncturing members into the skin or mucosa.
30. The method of claim 29 wherein said mechanism for producing vibrations comprises a piezo-electric transducer.
31. The method of claim 29 wherein said mechanism for producing vibrations produces vibrations in the range of about 2000 Hz to about 100 MHz.
32. The method of claim 18 further comprising an external reservoir for holding a liquid drug composition to be delivered to the body.
33. The method of claim 32 further comprising a mechanism for limiting the rate of drug delivery, said mechanism positioned between the external reservoir and the puncturing members.
34. The method of claim 18 wherein said device is disposable.
35. A method of transdermal or transmucosal monitoring of a selected analyte in a body comprising:
(a) providing a device comprising:
a base having a lower side and an upper side;
a plurality of puncturing members extending from the lower side of the base, said puncturing members configured for puncturing said skin or mucosa to a depth sufficient to reduce the barrier properties thereof without significantly damaging underlying tissues;
a plurality of holes extending from the lower side of the base to the upper side of the base, said holes configured for permitting a liquid to move therethrough by capillary action; and
a network of channels configured in the upper side of said base to interconnect said holes, said network of channels including a reservoir;
(b) contacting said device with the skin or mucosa such that said plurality of puncturing members puncture the skin or mucosa to a depth sufficient to reduce the barrier properties thereof resulting in seepage of interstitial fluid to the surface of said skin or mucosa such that interstitial fluid moves by capillary action through the holes, through the channels, to the reservoir;
(c) collecting the interstitial fluid from the reservoir; and
(d) analyzing the interstitial fluid with respect to the selected analyte.
36. The method of claim 35 further comprising applying suction to increase the rate of collection of interstitial fluid.
37. The method of claim 35 further comprising applying ultrasonic vibrations to the skin or mucosa to increase the rate of collection of the selected analyte.
38. The method of claim 37 wherein said ultrasonic vibrations are modulated in frequency, intensity, phase, or a combination thereof.
39. The method of claim 38 wherein said ultrasonic vibrations are in the range of about 2000 Hz to about 100 MHz.
40. The method of claim 35 wherein movement of interstitial fluid by capillary action is enhanced by applying ultrasonic vibrations.
41. The method of claim 35 wherein said selected analyte is glucose.
42. The method of claim 35 further comprising applying an anticoagulant to inhibit obstruction of the holes or channels.
43. A method of transdermally or transmucosally delivering a drug in liquid form to a body comprising:
(a) providing a device comprising:
a base having a lower side and an upper side;
a plurality of puncturing members extending from the lower side of the base, said puncturing members configured for puncturing said skin or mucosa to a depth sufficient to reduce the barrier properties thereof without significantly damaging underlying tissues;
a plurality of holes extending from the lower side of the base to the upper side of the base, said holes configured for permitting a liquid to move therethrough by capillary action; and
a network of channels configured in the upper side of said base to interconnect said holes, said network of channels including a reservoir;
(b) contacting said device with the skin or mucosa such that said plurality of puncturing members puncture the skin or mucosa to a depth sufficient to reduce the barrier properties thereof;
(c) supplying the drug to said reservoir such that said drug moves from the reservoir, through the channels and holes to the site of the punctures of the skin or mucosa and thus into the body.
44. The method of claim 43 further comprising applying pressure to increase the rate of delivery of the drug to the body.
45. The method of claim 43 further comprising applying ultrasonic vibrations to the skin or mucosa to increase the rate of delivery of the drug to the body.
46. The method of claim 45 wherein said ultrasonic vibrations are modulated in frequency, intensity, phase, or a combination thereof.
47. The method of claim 45 wherein said ultrasonic vibrations are in the range of about 2000 Hz to about 100 MHz.
48. The method of claim 43 wherein said drug in liquid form further comprises an anti-irritant, antiseptic, or analgesic to reduce trauma to the body due to the application of the device.
US09/852,935 1996-07-03 2001-05-10 Multiple mechanical microporation of skin or mucosa Abandoned US20020010412A1 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
US09/852,935 US20020010412A1 (en) 1996-07-03 2001-05-10 Multiple mechanical microporation of skin or mucosa

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US2121296P 1996-07-03 1996-07-03
US09/202,207 US6183434B1 (en) 1996-07-03 1997-07-03 Multiple mechanical microporation of skin or mucosa
US61416400A 2000-07-11 2000-07-11
US09/852,935 US20020010412A1 (en) 1996-07-03 2001-05-10 Multiple mechanical microporation of skin or mucosa

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
US61416400A Continuation 1996-07-03 2000-07-11

Publications (1)

Publication Number Publication Date
US20020010412A1 true US20020010412A1 (en) 2002-01-24

Family

ID=21802981

Family Applications (2)

Application Number Title Priority Date Filing Date
US09/202,207 Expired - Lifetime US6183434B1 (en) 1996-07-03 1997-07-03 Multiple mechanical microporation of skin or mucosa
US09/852,935 Abandoned US20020010412A1 (en) 1996-07-03 2001-05-10 Multiple mechanical microporation of skin or mucosa

Family Applications Before (1)

Application Number Title Priority Date Filing Date
US09/202,207 Expired - Lifetime US6183434B1 (en) 1996-07-03 1997-07-03 Multiple mechanical microporation of skin or mucosa

Country Status (10)

Country Link
US (2) US6183434B1 (en)
EP (1) EP0921840B1 (en)
JP (1) JP3942640B2 (en)
AT (1) ATE241405T1 (en)
AU (1) AU3880697A (en)
CA (1) CA2259437C (en)
DE (1) DE69722414T2 (en)
DK (1) DK0921840T3 (en)
ES (1) ES2200187T3 (en)
WO (1) WO1998000193A1 (en)

Cited By (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20040064087A1 (en) * 2002-08-29 2004-04-01 Lastovich Alexander G. Microabrader with controlled abrasion features
US20050119605A1 (en) * 2002-04-19 2005-06-02 Transpharma Medical Ltd. Handheld transdermal drug delivery and analyte extraction
US20080234626A1 (en) * 2006-04-26 2008-09-25 Chelak Todd M Multi-stage microporation device
US20080274166A1 (en) * 2005-06-10 2008-11-06 Transpharma Medical Ltd. Patch for Transdermal Drug Delivery
US20090053673A1 (en) * 2007-08-23 2009-02-26 Zimmer, Inc. Method for localized treatment of periodontal tissue
US20090118672A1 (en) * 2002-10-07 2009-05-07 Gonnelli Robert R Microneedle array patch
US20090187167A1 (en) * 2007-12-17 2009-07-23 New World Pharmaceuticals, Llc Integrated intra-dermal delivery, diagnostic and communication system
US20100229636A1 (en) * 2007-10-17 2010-09-16 Galit Levin Dissolution rate verification
US20100286588A1 (en) * 2007-10-09 2010-11-11 Transpharma Ltd. Magnetic patch coupling
US20100293807A1 (en) * 2007-10-29 2010-11-25 Transpharma Medical, Ltd. Vertical patch drying
EP2280645A2 (en) * 2008-05-02 2011-02-09 Aspect Medical Systems, Inc. Skin preparation device and biopotential sensor
US20110172645A1 (en) * 2010-01-08 2011-07-14 Ratio, Inc. Wearable drug delivery device including integrated pumping and activation elements
US20110172486A1 (en) * 2008-06-27 2011-07-14 Quentin Andrew Pankhurst Magnetic microbubbles, methods of preparing them and their uses
US20110172637A1 (en) * 2010-01-08 2011-07-14 Ratio, Inc. Drug delivery device including tissue support structure
US20110172639A1 (en) * 2010-01-08 2011-07-14 Ratio, Inc. Device and method for delivery of microneedle to desired depth within the skin
US20110172609A1 (en) * 2010-01-08 2011-07-14 Ratio, Inc. Microneedle component assembly for drug delivery device
WO2011109406A1 (en) * 2010-03-01 2011-09-09 Inovio Pharmaceuticals, Inc. A tolerable and minimally invasive skin electroporation device
US8668675B2 (en) 2010-11-03 2014-03-11 Flugen, Inc. Wearable drug delivery device having spring drive and sliding actuation mechanism
CN103687644A (en) * 2011-06-28 2014-03-26 艾诺奥医药品有限公司 A miniminally invasive dermal electroporation device
CN104508675A (en) * 2012-05-30 2015-04-08 斯科特·麦克纳尔蒂 System, method and apparatus for electromagnetic detection and analysis of biometric information
US9011419B2 (en) 2007-12-05 2015-04-21 Syneron Medical Ltd Disposable electromagnetic energy applicator
US9238102B2 (en) 2009-09-10 2016-01-19 Medipacs, Inc. Low profile actuator and improved method of caregiver controlled administration of therapeutics
US9500186B2 (en) 2010-02-01 2016-11-22 Medipacs, Inc. High surface area polymer actuator with gas mitigating components
US9504826B2 (en) 2009-02-18 2016-11-29 Syneron Medical Ltd Skin treatment apparatus for personal use and method for using same
US20170232246A1 (en) * 2014-11-07 2017-08-17 Toppan Printing Co., Ltd. Needle assembly for transdermal administration and method of producing the same
WO2018080923A1 (en) * 2016-10-28 2018-05-03 Georgetown University Non-invasive passive interstitial fluid collector
US9995295B2 (en) 2007-12-03 2018-06-12 Medipacs, Inc. Fluid metering device
US10000605B2 (en) 2012-03-14 2018-06-19 Medipacs, Inc. Smart polymer materials with excess reactive molecules
US10208158B2 (en) 2006-07-10 2019-02-19 Medipacs, Inc. Super elastic epoxy hydrogel
US11247206B2 (en) 2017-01-31 2022-02-15 Georgetown University Harvesting cell-free non-coding RNAS (CFNCRS) from interstitial fluid for sensitive biomarkers

Families Citing this family (242)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20060240381A1 (en) 1995-08-31 2006-10-26 Biolase Technology, Inc. Fluid conditioning system
US20090143775A1 (en) * 1995-08-31 2009-06-04 Rizoiu Ioana M Medical laser having controlled-temperature and sterilized fluid output
US20020010406A1 (en) 1996-05-17 2002-01-24 Douglas Joel S. Methods and apparatus for expressing body fluid from an incision
US7235056B2 (en) * 1996-05-17 2007-06-26 Amira Medical Body fluid sampling device and methods of use
US7828749B2 (en) 1996-05-17 2010-11-09 Roche Diagnostics Operations, Inc. Blood and interstitial fluid sampling device
EP1579814A3 (en) 1996-05-17 2006-06-14 Roche Diagnostics Operations, Inc. Methods and apparatus for sampling and analyzing body fluid
US6230051B1 (en) 1996-06-18 2001-05-08 Alza Corporation Device for enhancing transdermal agent delivery or sampling
DE69718495T2 (en) * 1996-09-17 2003-11-20 Deka Products Lp SYSTEM FOR DISPOSAL OF MEDICINE BY TRANSPORT
US6797276B1 (en) 1996-11-14 2004-09-28 The United States Of America As Represented By The Secretary Of The Army Use of penetration enhancers and barrier disruption agents to enhance the transcutaneous immune response
US5980898A (en) * 1996-11-14 1999-11-09 The United States Of America As Represented By The U.S. Army Medical Research & Material Command Adjuvant for transcutaneous immunization
US20060002949A1 (en) 1996-11-14 2006-01-05 Army Govt. Of The Usa, As Rep. By Secretary Of The Office Of The Command Judge Advocate, Hq Usamrmc. Transcutaneous immunization without heterologous adjuvant
US20060002959A1 (en) * 1996-11-14 2006-01-05 Government Of The United States Skin-sctive adjuvants for transcutaneous immuization
US20060149343A1 (en) * 1996-12-02 2006-07-06 Palomar Medical Technologies, Inc. Cooling system for a photocosmetic device
US6517532B1 (en) * 1997-05-15 2003-02-11 Palomar Medical Technologies, Inc. Light energy delivery head
US8182473B2 (en) * 1999-01-08 2012-05-22 Palomar Medical Technologies Cooling system for a photocosmetic device
JP2001512329A (en) * 1996-12-31 2001-08-21 アルテア テクノロジーズ,インコーポレイテッド Tissue microperforation for bioactive drug delivery
US6527716B1 (en) 1997-12-30 2003-03-04 Altea Technologies, Inc. Microporation of tissue for delivery of bioactive agents
JP4056091B2 (en) * 1997-05-15 2008-03-05 パロマー・メディカル・テクノロジーズ・インコーポレーテッド Dermatological treatment method and apparatus
US20040258703A1 (en) * 1997-11-14 2004-12-23 The Government Of The Us, As Represented By The Secretary Of The Army Skin-active adjuvants for transcutaneous immunization
US6706000B2 (en) * 1997-11-21 2004-03-16 Amira Medical Methods and apparatus for expressing body fluid from an incision
DE19800416C2 (en) * 1998-01-08 2002-09-19 Storz Karl Gmbh & Co Kg Device for the treatment of body tissue, in particular soft tissue close to the surface, by means of ultrasound
US6173202B1 (en) 1998-03-06 2001-01-09 Spectrx, Inc. Method and apparatus for enhancing flux rates of a fluid in a microporated biological tissue
ATE375752T1 (en) * 1998-03-06 2007-11-15 Spectrx Inc INTEGRATED TISSUE PORATION, FLUID COLLECTION AND ANALYSIS DEVICE
WO1999046005A1 (en) 1998-03-12 1999-09-16 Palomar Medical Technologies, Inc. System for electromagnetic radiation of the skin
EP1086214B1 (en) * 1998-06-10 2009-11-25 Georgia Tech Research Corporation Microneedle devices and methods of their manufacture
US6503231B1 (en) 1998-06-10 2003-01-07 Georgia Tech Research Corporation Microneedle device for transport of molecules across tissue
US7344499B1 (en) 1998-06-10 2008-03-18 Georgia Tech Research Corporation Microneedle device for extraction and sensing of bodily fluids
EP1090301B1 (en) 1998-06-24 2002-07-31 Transderm Technologies LLC Non-invasive transdermal detection of analytes
EP1199751A3 (en) * 1998-06-30 2005-12-07 Micronas GmbH Chip arrangement
US6352506B1 (en) 1998-07-14 2002-03-05 Altea Technologies Controlled removal of biological membrane by pyrotechnic charge for transmembrane transport
US7384396B2 (en) 1998-07-21 2008-06-10 Spectrx Inc. System and method for continuous analyte monitoring
US7037277B1 (en) 1998-07-21 2006-05-02 Spectrx, Inc. System and method for fluid management in a continuous fluid collection and sensor device
WO2000015102A1 (en) 1998-09-10 2000-03-23 Spectrx, Inc. Attribute compensation for analyte detection and/or continuous monitoring
US6597946B2 (en) * 1998-11-09 2003-07-22 Transpharma Ltd. Electronic card for transdermal drug delivery and analyte extraction
US6611706B2 (en) 1998-11-09 2003-08-26 Transpharma Ltd. Monopolar and bipolar current application for transdermal drug delivery and analyte extraction
US6708060B1 (en) 1998-11-09 2004-03-16 Transpharma Ltd. Handheld apparatus and method for transdermal drug delivery and analyte extraction
US6148232A (en) 1998-11-09 2000-11-14 Elecsys Ltd. Transdermal drug delivery and analyte extraction
EP1165132B1 (en) * 1999-04-08 2011-10-19 Intercell USA, Inc. Dry formulation for transcutaneous immunization
US6611707B1 (en) 1999-06-04 2003-08-26 Georgia Tech Research Corporation Microneedle drug delivery device
CA2376128C (en) * 1999-06-04 2009-01-06 Georgia Tech Research Corporation Devices and methods for enhanced microneedle penetration of biological barriers
US6743211B1 (en) 1999-11-23 2004-06-01 Georgia Tech Research Corporation Devices and methods for enhanced microneedle penetration of biological barriers
CA2376368C (en) * 1999-06-08 2009-08-11 Altea Technologies, Inc. Apparatus for microporation of biological membranes using thin film tissue interface devices, and method therefor
US6256533B1 (en) 1999-06-09 2001-07-03 The Procter & Gamble Company Apparatus and method for using an intracutaneous microneedle array
US6312612B1 (en) 1999-06-09 2001-11-06 The Procter & Gamble Company Apparatus and method for manufacturing an intracutaneous microneedle array
US6379324B1 (en) 1999-06-09 2002-04-30 The Procter & Gamble Company Intracutaneous microneedle array apparatus
US6925317B1 (en) 1999-06-11 2005-08-02 Spectrx, Inc. Integrated alignment devices, system, and methods for efficient fluid extraction, substance delivery and other applications
CA2376952A1 (en) 1999-06-11 2000-12-21 Mark A. Samuels Alignment devices and methods for fluid extraction from tissue and substance delivery
US6607495B1 (en) * 1999-06-18 2003-08-19 University Of Virginia Patent Foundation Apparatus for fluid transport and related method thereof
US20030078499A1 (en) * 1999-08-12 2003-04-24 Eppstein Jonathan A. Microporation of tissue for delivery of bioactive agents
US6623457B1 (en) 1999-09-22 2003-09-23 Becton, Dickinson And Company Method and apparatus for the transdermal administration of a substance
US6835184B1 (en) * 1999-09-24 2004-12-28 Becton, Dickinson And Company Method and device for abrading skin
ATE310561T1 (en) 1999-12-10 2005-12-15 Alza Corp APPARATUS AND METHOD FOR IMPROVING MICRONEEDLE SKIN PIERCING
IL150604A0 (en) * 2000-01-25 2003-02-12 Palomar Medical Tech Inc Method and apparatus for medical treatment utilizing long duration electromagnetic radiation
AU2001245472A1 (en) * 2000-03-09 2001-09-17 Nanopass Ltd. Systems and methods for the transport of fluids through a biological barrier andproduction techniques for such systems
US6595947B1 (en) 2000-05-22 2003-07-22 Becton, Dickinson And Company Topical delivery of vaccines
US6565532B1 (en) 2000-07-12 2003-05-20 The Procter & Gamble Company Microneedle apparatus used for marking skin and for dispensing semi-permanent subcutaneous makeup
US6540675B2 (en) * 2000-06-27 2003-04-01 Rosedale Medical, Inc. Analyte monitor
US6440096B1 (en) * 2000-07-14 2002-08-27 Becton, Dickinson And Co. Microdevice and method of manufacturing a microdevice
RU2272618C2 (en) 2000-09-08 2006-03-27 Алза Корпорейшн Method for inhibiting reduction of transdermal drug movement by inhibiting paths closing
EP1335764B1 (en) * 2000-09-08 2007-06-06 Insulet Corporation Device and system for patient infusion
JP2002085561A (en) * 2000-09-14 2002-03-26 Terumo Corp Liquid injection needle
WO2002030506A2 (en) * 2000-10-12 2002-04-18 Ink Jet Technology Ltd. Transdermal method
US7419481B2 (en) 2000-10-13 2008-09-02 Alza Corporation Apparatus and method for piercing skin with microprotrusions
US6882884B1 (en) 2000-10-13 2005-04-19 Soundskin, L.L.C. Process for the stimulation of production of extracellular dermal proteins in human tissue
HUP0303576A2 (en) 2000-10-13 2004-01-28 Alza Corp Microprotrusion member retainer for impact applicator
CN100391404C (en) 2000-10-13 2008-06-04 阿尔扎公司 Microblade array impact applicator
NZ525294A (en) 2000-10-13 2005-02-25 Alza Corp Apparatus and method for piercing skin with microprotrusions
US7828827B2 (en) 2002-05-24 2010-11-09 Corium International, Inc. Method of exfoliation of skin using closely-packed microstructures
US7131987B2 (en) 2000-10-16 2006-11-07 Corium International, Inc. Microstructures and method for treating and conditioning skin which cause less irritation during exfoliation
US6821281B2 (en) 2000-10-16 2004-11-23 The Procter & Gamble Company Microstructures for treating and conditioning skin
CA2427381A1 (en) 2000-10-26 2002-11-28 Alza Corporation Transdermal drug delivery devices having coated microprotrusions
WO2002064193A2 (en) 2000-12-14 2002-08-22 Georgia Tech Research Corporation Microneedle devices and production thereof
AU2002231207A1 (en) 2000-12-21 2002-07-01 Biovalve Technologies, Inc. Microneedle array systems
US20060004347A1 (en) * 2000-12-28 2006-01-05 Palomar Medical Technologies, Inc. Methods and products for producing lattices of EMR-treated islets in tissues, and uses therefor
US20080214988A1 (en) * 2000-12-28 2008-09-04 Palomar Medical Technologies, Inc. Methods And Devices For Fractional Ablation Of Tissue
AU2002306576A1 (en) 2001-02-23 2002-09-12 Technical Graphics Security Products, Llc Security label having security element and method of making same
US6888319B2 (en) * 2001-03-01 2005-05-03 Palomar Medical Technologies, Inc. Flashlamp drive circuit
EP1365699A2 (en) * 2001-03-02 2003-12-03 Palomar Medical Technologies, Inc. Apparatus and method for photocosmetic and photodermatological treatment
US6663820B2 (en) 2001-03-14 2003-12-16 The Procter & Gamble Company Method of manufacturing microneedle structures using soft lithography and photolithography
US6855372B2 (en) 2001-03-16 2005-02-15 Alza Corporation Method and apparatus for coating skin piercing microprojections
EP1752189A3 (en) 2001-04-20 2007-02-21 Alza Corporation Microprojection array having a beneficial agent containing coating
DE60233939D1 (en) 2001-04-20 2009-11-19 Alza Corp MICROPROJECTION ARRANGEMENT WITH A COATING CONTAINING ADVANTAGEOUS MEDIUM
US20070042315A1 (en) * 2005-06-24 2007-02-22 Biolase Technology, Inc. Visual feedback implements for electromagnetic energy output devices
US6591124B2 (en) 2001-05-11 2003-07-08 The Procter & Gamble Company Portable interstitial fluid monitoring system
US6840910B2 (en) 2001-08-01 2005-01-11 Johnson & Johnson Consumer Companies, Inc. Method of distributing skin care products
US6855117B2 (en) 2001-08-01 2005-02-15 Johnson & Johnson Consumer Companies, Inc. Method of treating the skin of a subject
US6790179B2 (en) 2001-08-01 2004-09-14 Johnson & Johnson Consumer Companies, Inc. Method of examining and diagnosing skin health
US20020188223A1 (en) 2001-06-08 2002-12-12 Edward Perez Devices and methods for the expression of bodily fluids from an incision
AU2002312380A1 (en) * 2001-06-08 2002-12-23 Becton, Dickinson And Company Device for manipulating a needle or abrader array
US6793632B2 (en) 2001-06-12 2004-09-21 Lifescan, Inc. Percutaneous biological fluid constituent sampling and measurement devices and methods
US6721586B2 (en) 2001-06-12 2004-04-13 Lifescan, Inc. Percutaneous biological fluid sampling and analyte measurement devices and methods
US6875613B2 (en) 2001-06-12 2005-04-05 Lifescan, Inc. Biological fluid constituent sampling and measurement devices and methods
US6501976B1 (en) 2001-06-12 2002-12-31 Lifescan, Inc. Percutaneous biological fluid sampling and analyte measurement devices and methods
US6837988B2 (en) 2001-06-12 2005-01-04 Lifescan, Inc. Biological fluid sampling and analyte measurement devices and methods
US20030028125A1 (en) * 2001-08-06 2003-02-06 Yuzhakov Vadim V. Physiological sample collection devices and methods of using the same
US6881203B2 (en) * 2001-09-05 2005-04-19 3M Innovative Properties Company Microneedle arrays and methods of manufacturing the same
JP2005503210A (en) * 2001-09-14 2005-02-03 ザ プロクター アンド ギャンブル カンパニー Microstructure for delivering compositions to the skin through the skin using a rotatable structure
US20040087992A1 (en) * 2002-08-09 2004-05-06 Vladimir Gartstein Microstructures for delivering a composition cutaneously to skin using rotatable structures
WO2003024507A2 (en) 2001-09-19 2003-03-27 Biovalve Technologies, Inc. Microneedles, microneedle arrays, and systems and methods relating to same
WO2003024508A2 (en) 2001-09-21 2003-03-27 Biovalve Technologies, Inc. Gas pressure actuated microneedle arrays, and systems and methods relating to same
US7429258B2 (en) * 2001-10-26 2008-09-30 Massachusetts Institute Of Technology Microneedle transport device
US20040120964A1 (en) * 2001-10-29 2004-06-24 Mikszta John A. Needleless vaccination using chimeric yellow fever vaccine-vectored vaccines against heterologous flaviviruses
JP2005511248A (en) * 2001-10-29 2005-04-28 ベクトン・ディキンソン・アンド・カンパニー Methods and devices for delivering substances
US20040147984A1 (en) * 2001-11-29 2004-07-29 Palomar Medical Technologies, Inc. Methods and apparatus for delivering low power optical treatments
US6952604B2 (en) * 2001-12-21 2005-10-04 Becton, Dickinson And Company Minimally-invasive system and method for monitoring analyte levels
WO2003057059A1 (en) * 2001-12-27 2003-07-17 Palomar Medical Technologies, Inc. Method and apparatus for improved vascular related treatment
US20040073175A1 (en) * 2002-01-07 2004-04-15 Jacobson James D. Infusion system
US6908453B2 (en) * 2002-01-15 2005-06-21 3M Innovative Properties Company Microneedle devices and methods of manufacture
MXPA04007389A (en) 2002-02-04 2004-10-11 Becton Dickinson Co Device and method for delivering or withdrawing a substance through the skin.
US7004928B2 (en) * 2002-02-08 2006-02-28 Rosedale Medical, Inc. Autonomous, ambulatory analyte monitor or drug delivery device
EP2319578B1 (en) * 2002-03-11 2016-11-02 Nitto Denko Corporation Transdermal drug delievery patch system, method of making same and method of using same
US9918665B2 (en) 2002-03-11 2018-03-20 Nitto Denko Corporation Transdermal porator and patch system and method for using same
US8116860B2 (en) 2002-03-11 2012-02-14 Altea Therapeutics Corporation Transdermal porator and patch system and method for using same
US7060192B2 (en) 2002-05-09 2006-06-13 Lifescan, Inc. Methods of fabricating physiological sample collection devices
US20070239142A1 (en) * 2006-03-10 2007-10-11 Palomar Medical Technologies, Inc. Photocosmetic device
BR0312430A (en) 2002-06-19 2005-04-26 Palomar Medical Tech Inc Method and apparatus for treating skin and subcutaneous conditions
BR0311901A (en) * 2002-06-19 2005-04-05 Gen Hospital Corp Process and apparatus for photothermal deep tissue treatment
KR101323980B1 (en) * 2002-07-19 2013-10-30 쓰리엠 이노베이티브 프로퍼티즈 컴파니 Microneedle device, method of using microneedle device and method of delivering microneedle device
US20070219604A1 (en) * 2006-03-20 2007-09-20 Palomar Medical Technologies, Inc. Treatment of tissue with radiant energy
EP2522293A2 (en) * 2002-10-23 2012-11-14 Palomar Medical Technologies, Inc. Phototreatment device for use with coolants and topical substances
WO2004058352A2 (en) * 2002-12-20 2004-07-15 Palomar Medical Technologies, Inc. Apparatus for light treatment of acne and other disorders of follicles
CA2515843A1 (en) * 2003-02-19 2004-09-02 Palomar Medical Technologies, Inc. Method and apparatus for treating pseudofolliculitis barbae
US7578954B2 (en) * 2003-02-24 2009-08-25 Corium International, Inc. Method for manufacturing microstructures having multiple microelements with through-holes
US7052652B2 (en) 2003-03-24 2006-05-30 Rosedale Medical, Inc. Analyte concentration detection devices and methods
US20080149524A1 (en) * 2003-03-27 2008-06-26 Rademaker William B Food containers including dental cleaning devices and other personal care items
ES2737835T3 (en) 2003-04-23 2020-01-16 Valeritas Inc Hydraulically driven pump for long-term medication administration
JP2004343275A (en) * 2003-05-14 2004-12-02 Murata Mach Ltd Image processing system and scanner
EP1638523B8 (en) 2003-06-30 2013-12-25 ALZA Corporation Formulations for coated microprojections containing non-volatile counterions
US20050059166A1 (en) * 2003-09-11 2005-03-17 Robert Markes Sampling instrument
US8016811B2 (en) * 2003-10-24 2011-09-13 Altea Therapeutics Corporation Method for transdermal delivery of permeant substances
CN1897898A (en) 2003-10-24 2007-01-17 阿尔扎公司 Pretreatment method and system for enhancing transdermal drug delivery
WO2005044139A2 (en) 2003-10-28 2005-05-19 Alza Corporation Method and apparatus for reducing the incidence of tobacco use
AU2004287414B2 (en) 2003-10-31 2010-11-25 Alza Corporation Self-actuating applicator for microprojection array
CA2546723A1 (en) * 2003-11-21 2005-06-09 Alza Corporation Ultrasound assisted transdermal vaccine delivery method and system
MXPA06006041A (en) * 2003-11-28 2007-01-31 Acrux Dds Pty Ltd Method and system for rapid transdermal administration.
WO2005065565A1 (en) * 2003-12-31 2005-07-21 Palomar Medical Technologies, Inc. Dermatological treatment with vusualization
US20100151406A1 (en) 2004-01-08 2010-06-17 Dmitri Boutoussov Fluid conditioning system
KR20060134050A (en) * 2004-01-09 2006-12-27 알자 코포레이션 Frequency assisted transdermal agent delivery method and system
PL1725168T3 (en) 2004-03-06 2016-10-31 Body fluid sampling device
US7819822B2 (en) * 2004-03-06 2010-10-26 Roche Diagnostics Operations, Inc. Body fluid sampling device
AU2005228145B2 (en) * 2004-03-24 2011-03-03 Corium Pharma Solutions, Inc. Transdermal delivery device
JP5065005B2 (en) 2004-04-01 2012-10-31 ザ ジェネラル ホスピタル コーポレイション Method and apparatus for dermatological treatment and tissue remodeling
JP4981660B2 (en) * 2004-04-12 2012-07-25 アラーガン、インコーポレイテッド Multi-site injection system
US7315758B2 (en) 2004-06-03 2008-01-01 Lynntech, Inc. Transdermal delivery of therapeutic agent
WO2006014425A1 (en) * 2004-07-02 2006-02-09 Biovalve Technologies, Inc. Methods and devices for delivering glp-1 and uses thereof
AU2005299759A1 (en) * 2004-10-21 2006-05-04 Bayer Healthcare Llc Method of determining the concentration of an analyte in a body fluid and system therefor
US20060253176A1 (en) * 2005-02-18 2006-11-09 Palomar Medical Technologies, Inc. Dermatological treatment device with deflector optic
BRPI0607903A2 (en) * 2005-02-18 2009-10-20 Palomar Medical Tech Inc dermatological treatment device
US7856985B2 (en) 2005-04-22 2010-12-28 Cynosure, Inc. Method of treatment body tissue using a non-uniform laser beam
BRPI0611186A2 (en) * 2005-06-03 2010-08-24 Biolase Tech Inc Tissue treatment device and method
US20060281187A1 (en) * 2005-06-13 2006-12-14 Rosedale Medical, Inc. Analyte detection devices and methods with hematocrit/volume correction and feedback control
TWI419717B (en) * 2005-06-17 2013-12-21 Altea Therapeutics Corp Permeant delivery system and methods for use thereof
AU2006292526A1 (en) 2005-09-15 2007-03-29 Palomar Medical Technologies, Inc. Skin optical characterization device
US8801631B2 (en) 2005-09-30 2014-08-12 Intuity Medical, Inc. Devices and methods for facilitating fluid transport
CA2623589C (en) * 2005-09-30 2014-07-22 Intuity Medical, Inc. Catalysts for body fluid sample extraction
US20070194717A1 (en) * 2006-02-17 2007-08-23 Palomar Medical Technologies, Inc. Lamp for use in a tissue treatment device
CA2646324C (en) 2006-03-30 2016-06-07 Valeritas, Llc Multi-cartridge fluid delivery device
WO2007117580A2 (en) * 2006-04-06 2007-10-18 Palomar Medical Technologies, Inc. Apparatus and method for skin treatment with compression and decompression
US7662177B2 (en) * 2006-04-12 2010-02-16 Bacoustics, Llc Apparatus and methods for pain relief using ultrasound waves in combination with cryogenic energy
JP4265696B2 (en) * 2006-07-04 2009-05-20 凸版印刷株式会社 Manufacturing method of microneedle
EP2047882B1 (en) * 2006-07-27 2014-09-10 Toppan Printing Co., Ltd. Microneedle and method for producing microneedle
US7586957B2 (en) 2006-08-02 2009-09-08 Cynosure, Inc Picosecond laser apparatus and methods for its operation and use
US20080152592A1 (en) * 2006-12-21 2008-06-26 Bayer Healthcare Llc Method of therapeutic drug monitoring
AU2008209537B2 (en) * 2007-01-22 2013-01-31 Corium Pharma Solutions, Inc. Applicators for microneedle arrays
US9101377B2 (en) * 2007-01-25 2015-08-11 Biolase, Inc. Electromagnetic energy output system
US7815630B2 (en) * 2007-01-25 2010-10-19 Biolase Technology, Inc. Target-close electromagnetic energy emitting device
US7695469B2 (en) * 2007-01-25 2010-04-13 Biolase Technology, Inc. Electromagnetic energy output system
US20080186591A1 (en) * 2007-02-01 2008-08-07 Palomar Medical Technologies, Inc. Dermatological device having a zoom lens system
ES2817249T3 (en) 2007-04-16 2021-04-06 Corium Inc Microneedle matrices obtained by dissolution and casting containing an active principle
US20090225060A1 (en) * 2007-05-03 2009-09-10 Rizoiu Ioana M Wrist-mounted laser with animated, page-based graphical user-interface
US8143034B2 (en) * 2007-08-21 2012-03-27 Polytechnic Institute Of New York University Method for preparing long-chain hydroxyacids, diacids and oligomers and polymers thereof
WO2009048607A1 (en) 2007-10-10 2009-04-16 Corium International, Inc. Vaccine delivery via microneedle arrays
JP5178132B2 (en) * 2007-10-11 2013-04-10 キヤノン株式会社 Image processing system and image processing method
WO2009145920A1 (en) 2008-05-30 2009-12-03 Intuity Medical, Inc. Body fluid sampling device -- sampling site interface
ES2907152T3 (en) 2008-06-06 2022-04-22 Intuity Medical Inc Blood glucose meter and method of operation
JP5642066B2 (en) 2008-06-06 2014-12-17 インテュイティ メディカル インコーポレイテッド Method and apparatus for performing an assay to determine the presence or concentration of an analyte contained in a sample of body fluid
KR101013581B1 (en) * 2008-08-06 2011-02-14 라종주 Electric Skin Treatment Device
US7959598B2 (en) 2008-08-20 2011-06-14 Asante Solutions, Inc. Infusion pump systems and methods
TW201027393A (en) 2009-01-06 2010-07-16 Pixart Imaging Inc Electronic apparatus with virtual data input device
ES2634667T3 (en) * 2009-04-24 2017-09-28 Corium International, Inc. Methods for manufacturing microprojection assemblies
US9919168B2 (en) 2009-07-23 2018-03-20 Palomar Medical Technologies, Inc. Method for improvement of cellulite appearance
US9017310B2 (en) * 2009-10-08 2015-04-28 Palo Alto Research Center Incorporated Transmucosal drug delivery device and method including microneedles
US9014799B2 (en) * 2009-10-08 2015-04-21 Palo Alto Research Center Incorporated Transmucosal drug delivery device and method including electrically-actuated permeation enhancement
US8882748B2 (en) 2009-10-08 2014-11-11 Palo Alto Research Center Incorporated Transmucosal drug delivery device and method including chemical permeation enhancers
EP2506768B1 (en) 2009-11-30 2016-07-06 Intuity Medical, Inc. Calibration material delivery devices and methods
ES2719595T3 (en) 2010-05-04 2019-07-11 Corium Int Inc Method and device for transdermal administration of parathyroid hormone using a microprojection matrix
EP2584964B1 (en) 2010-06-25 2021-08-04 Intuity Medical, Inc. Analyte monitoring devices
EP4339613A2 (en) 2011-08-03 2024-03-20 Intuity Medical, Inc. Body fluid sampling arrangement
EP2830499B8 (en) 2012-03-30 2019-04-03 Insulet Corporation Fluid delivery device with transcutaneous access tool, insertion mechansim and blood glucose monitoring for use therewith
US9780518B2 (en) 2012-04-18 2017-10-03 Cynosure, Inc. Picosecond laser apparatus and methods for treating target tissues with same
KR101372403B1 (en) * 2012-06-21 2014-03-25 주식회사 파나시 Pressure Sensitive Automatic Injection System
US9999720B2 (en) 2012-09-27 2018-06-19 Palo Alto Research Center Incorporated Drug reconstitution and delivery device and methods
US9005108B2 (en) 2012-09-27 2015-04-14 Palo Alto Research Center Incorporated Multiple reservoir drug delivery device and methods
WO2014073531A1 (en) 2012-11-09 2014-05-15 凸版印刷株式会社 Needle-like structure and method for manufacturing same
CA2896188C (en) 2012-12-21 2021-02-23 Corium International, Inc. Microarray for delivery of therapeutic agent and methods of use
US9744341B2 (en) 2013-01-15 2017-08-29 Palo Alto Research Center Incorporated Devices and methods for intraluminal retention and drug delivery
AU2014249471B2 (en) 2013-03-12 2019-01-24 Corium Pharma Solutions, Inc. Microprojection applicators
EP2973894A2 (en) 2013-03-15 2016-01-20 Cynosure, Inc. Picosecond optical radiation systems and methods of use
JP2016512754A (en) 2013-03-15 2016-05-09 コリウム インターナショナル, インコーポレイテッド Microarray, method of use and manufacturing for delivery of therapeutic agents
CA2903763C (en) 2013-03-15 2021-11-16 Corium International, Inc. Microarray with polymer-free microstructures, methods of making, and methods of use
MX2015012933A (en) 2013-03-15 2016-09-19 Corium Int Inc Microarray for delivery of therapeutic agent and methods of use.
ES2939317T3 (en) 2013-03-15 2023-04-20 Corium Pharma Solutions Inc Multi-impact micro-spray applicators
US20140350518A1 (en) 2013-05-23 2014-11-27 Allergan, Inc. Syringe extrusion accessory
US20140350516A1 (en) 2013-05-23 2014-11-27 Allergan, Inc. Mechanical syringe accessory
JP2016522070A (en) 2013-06-21 2016-07-28 インテュイティ メディカル インコーポレイテッド Analyte monitoring system using audible feedback
US20150038897A1 (en) 2013-07-30 2015-02-05 Zosano Pharma, Inc. Low-Profile Microneedle Patch Applicator
US9297083B2 (en) 2013-12-16 2016-03-29 Palo Alto Research Center Incorporated Electrolytic gas generating devices, actuators, and methods
GB2523989B (en) 2014-01-30 2020-07-29 Insulet Netherlands B V Therapeutic product delivery system and method of pairing
US10029048B2 (en) 2014-05-13 2018-07-24 Allergan, Inc. High force injection devices
JP6565906B2 (en) 2014-05-20 2019-08-28 凸版印刷株式会社 Needle-like body manufacturing method and needle-like body
US10278675B2 (en) 2014-07-31 2019-05-07 Palo Alto Research Center Incorporated Implantable estrus detection devices, systems, and methods
US9801660B2 (en) 2014-07-31 2017-10-31 Palo Alto Research Center Incorporated Implantable fluid delivery devices, systems, and methods
US10624843B2 (en) 2014-09-04 2020-04-21 Corium, Inc. Microstructure array, methods of making, and methods of use
US10226585B2 (en) 2014-10-01 2019-03-12 Allergan, Inc. Devices for injection and dosing
EP3258991B1 (en) 2015-02-18 2020-10-21 Insulet Corporation Fluid delivery and infusion devices, and methods of use thereof
EP3268063A4 (en) 2015-03-10 2018-10-31 Allergan Pharmaceuticals Holdings (Ireland) Unlimited Company Multiple needle injector
WO2017004067A1 (en) 2015-06-29 2017-01-05 Corium International, Inc. Microarray for delivery of therapeutic agent, methods of use, and methods of making
US10716896B2 (en) 2015-11-24 2020-07-21 Insulet Corporation Wearable automated medication delivery system
US10413665B2 (en) 2015-11-25 2019-09-17 Insulet Corporation Wearable medication delivery device
US10275573B2 (en) 2016-01-13 2019-04-30 Bigfoot Biomedical, Inc. User interface for diabetes management system
US10780223B2 (en) 2016-01-14 2020-09-22 Bigfoot Biomedical, Inc. Adjusting insulin delivery rates
WO2017136268A1 (en) 2016-02-04 2017-08-10 Insulet Corporation Anti-inflammatory cannula
EP3439716B1 (en) 2016-04-08 2023-11-01 Allergan, Inc. Aspiration and injection device
EP3515535A1 (en) 2016-09-23 2019-07-31 Insulet Corporation Fluid delivery device with sensor
US11045603B2 (en) 2017-02-22 2021-06-29 Insulet Corporation Needle insertion mechanisms for drug containers
USD867582S1 (en) 2017-03-24 2019-11-19 Allergan, Inc. Syringe device
US10898656B2 (en) 2017-09-26 2021-01-26 Insulet Corporation Needle mechanism module for drug delivery device
US11147931B2 (en) 2017-11-17 2021-10-19 Insulet Corporation Drug delivery device with air and backflow elimination
KR102627248B1 (en) 2018-02-26 2024-01-19 싸이노슈어, 엘엘씨 Q-switched cavity dumping subnanosecond laser
WO2019213493A1 (en) 2018-05-04 2019-11-07 Insulet Corporation Safety constraints for a control algorithm-based drug delivery system
CN112789070A (en) 2018-09-28 2021-05-11 英赛罗公司 Mode of activity of the artificial pancreas System
EP3864668A1 (en) 2018-10-11 2021-08-18 Insulet Corporation Event detection for drug delivery system
US11801344B2 (en) 2019-09-13 2023-10-31 Insulet Corporation Blood glucose rate of change modulation of meal and correction insulin bolus quantity
US11833329B2 (en) 2019-12-20 2023-12-05 Insulet Corporation Techniques for improved automatic drug delivery performance using delivery tendencies from past delivery history and use patterns
US11551802B2 (en) 2020-02-11 2023-01-10 Insulet Corporation Early meal detection and calorie intake detection
US11547800B2 (en) 2020-02-12 2023-01-10 Insulet Corporation User parameter dependent cost function for personalized reduction of hypoglycemia and/or hyperglycemia in a closed loop artificial pancreas system
US11324889B2 (en) 2020-02-14 2022-05-10 Insulet Corporation Compensation for missing readings from a glucose monitor in an automated insulin delivery system
US11607493B2 (en) 2020-04-06 2023-03-21 Insulet Corporation Initial total daily insulin setting for user onboarding
US11684716B2 (en) 2020-07-31 2023-06-27 Insulet Corporation Techniques to reduce risk of occlusions in drug delivery systems
US11904140B2 (en) 2021-03-10 2024-02-20 Insulet Corporation Adaptable asymmetric medicament cost component in a control system for medicament delivery
US11738144B2 (en) 2021-09-27 2023-08-29 Insulet Corporation Techniques enabling adaptation of parameters in aid systems by user input
US11439754B1 (en) 2021-12-01 2022-09-13 Insulet Corporation Optimizing embedded formulations for drug delivery

Family Cites Families (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3964482A (en) * 1971-05-17 1976-06-22 Alza Corporation Drug delivery device
US4340048A (en) * 1981-03-28 1982-07-20 Alza Corporation Self-driven hypodermic injector
US4522622A (en) * 1982-12-23 1985-06-11 Alza Corporation Multiple fluid pulse dispenser
US4775361A (en) * 1986-04-10 1988-10-04 The General Hospital Corporation Controlled removal of human stratum corneum by pulsed laser to enhance percutaneous transport
GB2221394B (en) 1988-08-05 1992-03-04 Eilert Eilertsen An injection device
US5169389A (en) * 1989-06-16 1992-12-08 Science, Inc. Fluid delivery apparatus
EP0429842B1 (en) * 1989-10-27 1996-08-28 Korea Research Institute Of Chemical Technology Device for the transdermal administration of protein or peptide drug
US5115805A (en) 1990-02-23 1992-05-26 Cygnus Therapeutic Systems Ultrasound-enhanced delivery of materials into and through the skin
US5137817A (en) * 1990-10-05 1992-08-11 Amoco Corporation Apparatus and method for electroporation
US5279544A (en) 1990-12-13 1994-01-18 Sil Medics Ltd. Transdermal or interdermal drug delivery devices
US5312456A (en) 1991-01-31 1994-05-17 Carnegie Mellon University Micromechanical barb and method for making the same
US5223219A (en) 1992-04-10 1993-06-29 Biotrack, Inc. Analytical cartridge and system for detecting analytes in liquid samples
US5421816A (en) 1992-10-14 1995-06-06 Endodermic Medical Technologies Company Ultrasonic transdermal drug delivery system
US5582184A (en) * 1993-10-13 1996-12-10 Integ Incorporated Interstitial fluid collection and constituent measurement
US5458140A (en) * 1993-11-15 1995-10-17 Non-Invasive Monitoring Company (Nimco) Enhancement of transdermal monitoring applications with ultrasound and chemical enhancers
US5445611A (en) * 1993-12-08 1995-08-29 Non-Invasive Monitoring Company (Nimco) Enhancement of transdermal delivery with ultrasound and chemical enhancers
DE59505328D1 (en) 1994-12-09 1999-04-15 Novartis Ag TRANSDERMAL SYSTEM
TR199800347T1 (en) * 1995-08-29 1998-05-21 Spectrx, Inc. Micro-poring of human skin for drug application and monitoring applications.
US5801057A (en) 1996-03-22 1998-09-01 Smart; Wilson H. Microsampling device and method of construction
JP2828064B2 (en) * 1996-09-20 1998-11-25 日本電気株式会社 Suction leachate collection method and device
US6071249A (en) 1996-12-06 2000-06-06 Abbott Laboratories Method and apparatus for obtaining blood for diagnostic tests
JP2001512329A (en) * 1996-12-31 2001-08-21 アルテア テクノロジーズ,インコーポレイテッド Tissue microperforation for bioactive drug delivery
US6155992A (en) 1997-12-02 2000-12-05 Abbott Laboratories Method and apparatus for obtaining interstitial fluid for diagnostic tests
WO1999040848A1 (en) 1998-02-17 1999-08-19 Abbott Laboratories Interstitial fluid collection and monitoring device
US6022316A (en) * 1998-03-06 2000-02-08 Spectrx, Inc. Apparatus and method for electroporation of microporated tissue for enhancing flux rates for monitoring and delivery applications

Cited By (52)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20050119605A1 (en) * 2002-04-19 2005-06-02 Transpharma Medical Ltd. Handheld transdermal drug delivery and analyte extraction
US8337493B2 (en) 2002-04-19 2012-12-25 Syneron Medical Ltd Handheld transdermal drug delivery and analyte extraction
US20110178518A1 (en) * 2002-04-19 2011-07-21 Transpharma Medical, Ltd. Handheld transdermal drug delivery and analyte extraction
US20090270792A1 (en) * 2002-08-29 2009-10-29 Lastovich Alexander G Microprotrusion arrays and methods for using same to deliver substances into tissue
US20040077994A1 (en) * 2002-08-29 2004-04-22 Lastovich Alexander G. Microprotrusion arrays and methods for using same to deliver substances into tissue
US7166086B2 (en) 2002-08-29 2007-01-23 Becton, Dickinson And Company Substance delivery via a rotating microabrading surface
US7316671B2 (en) 2002-08-29 2008-01-08 Becton, Dickinson And Company Microprotrusion arrays and methods for using same to deliver substances into tissue
US7422567B2 (en) 2002-08-29 2008-09-09 Becton, Dickinson And Company Microabrader with controlled abrasion features
US8075826B2 (en) 2002-08-29 2011-12-13 Becton, Dickinson And Company Microprotrusion arrays and methods for using same to deliver substances into tissue
US20040064087A1 (en) * 2002-08-29 2004-04-01 Lastovich Alexander G. Microabrader with controlled abrasion features
US20090118672A1 (en) * 2002-10-07 2009-05-07 Gonnelli Robert R Microneedle array patch
US8162901B2 (en) 2002-10-07 2012-04-24 Valeritas, Inc. Microneedle array patch
US20080274166A1 (en) * 2005-06-10 2008-11-06 Transpharma Medical Ltd. Patch for Transdermal Drug Delivery
US20080234626A1 (en) * 2006-04-26 2008-09-25 Chelak Todd M Multi-stage microporation device
US10208158B2 (en) 2006-07-10 2019-02-19 Medipacs, Inc. Super elastic epoxy hydrogel
US20090053673A1 (en) * 2007-08-23 2009-02-26 Zimmer, Inc. Method for localized treatment of periodontal tissue
US20100286588A1 (en) * 2007-10-09 2010-11-11 Transpharma Ltd. Magnetic patch coupling
US9037229B2 (en) 2007-10-09 2015-05-19 Syneron Medical Ltd Magnetic patch coupling
US8281675B2 (en) 2007-10-17 2012-10-09 Syneron Medical Ltd Dissolution rate verification
US20100229636A1 (en) * 2007-10-17 2010-09-16 Galit Levin Dissolution rate verification
US20100293807A1 (en) * 2007-10-29 2010-11-25 Transpharma Medical, Ltd. Vertical patch drying
US9995295B2 (en) 2007-12-03 2018-06-12 Medipacs, Inc. Fluid metering device
US9011419B2 (en) 2007-12-05 2015-04-21 Syneron Medical Ltd Disposable electromagnetic energy applicator
US9022973B2 (en) 2007-12-17 2015-05-05 New World Pharmaceuticals, Llc Integrated intra-dermal delivery, diagnostic and communication system
US10384005B2 (en) 2007-12-17 2019-08-20 New World Pharmaceuticals, Llc Integrated intra-dermal delivery, diagnostic and communication system
US20090187167A1 (en) * 2007-12-17 2009-07-23 New World Pharmaceuticals, Llc Integrated intra-dermal delivery, diagnostic and communication system
EP2280645A2 (en) * 2008-05-02 2011-02-09 Aspect Medical Systems, Inc. Skin preparation device and biopotential sensor
EP2280645A4 (en) * 2008-05-02 2013-09-18 Aspect Medical Systems Inc Skin preparation device and biopotential sensor
US20110172486A1 (en) * 2008-06-27 2011-07-14 Quentin Andrew Pankhurst Magnetic microbubbles, methods of preparing them and their uses
US9427396B2 (en) 2008-06-27 2016-08-30 Ucl Business Plc Magnetic microbubbles, methods of preparing them and their uses
US9504826B2 (en) 2009-02-18 2016-11-29 Syneron Medical Ltd Skin treatment apparatus for personal use and method for using same
US9238102B2 (en) 2009-09-10 2016-01-19 Medipacs, Inc. Low profile actuator and improved method of caregiver controlled administration of therapeutics
US20110172639A1 (en) * 2010-01-08 2011-07-14 Ratio, Inc. Device and method for delivery of microneedle to desired depth within the skin
US20110172645A1 (en) * 2010-01-08 2011-07-14 Ratio, Inc. Wearable drug delivery device including integrated pumping and activation elements
US20110172637A1 (en) * 2010-01-08 2011-07-14 Ratio, Inc. Drug delivery device including tissue support structure
US20110172609A1 (en) * 2010-01-08 2011-07-14 Ratio, Inc. Microneedle component assembly for drug delivery device
US9500186B2 (en) 2010-02-01 2016-11-22 Medipacs, Inc. High surface area polymer actuator with gas mitigating components
CN102905755A (en) * 2010-03-01 2013-01-30 因诺维奥制药公司 A tolerable and minimally invasive skin electroporation device
WO2011109406A1 (en) * 2010-03-01 2011-09-09 Inovio Pharmaceuticals, Inc. A tolerable and minimally invasive skin electroporation device
AU2011223753B2 (en) * 2010-03-01 2014-06-26 Inovio Pharmaceuticals, Inc. A tolerable and minimally invasive skin electroporation device
US11565107B2 (en) * 2010-03-01 2023-01-31 Inovio Pharmaceuticals, Inc. Tolerable and minimally invasive skin electroporation device
EA025705B1 (en) * 2010-03-01 2017-01-30 Иновио Фармасьютикалз, Инк. Tolerable and minimally invasive skin electroporation device
US20130066296A1 (en) * 2010-03-01 2013-03-14 Kate Broderick Tolerable and minimally invasive skin electroporation device
US8668675B2 (en) 2010-11-03 2014-03-11 Flugen, Inc. Wearable drug delivery device having spring drive and sliding actuation mechanism
CN103687644A (en) * 2011-06-28 2014-03-26 艾诺奥医药品有限公司 A miniminally invasive dermal electroporation device
US10000605B2 (en) 2012-03-14 2018-06-19 Medipacs, Inc. Smart polymer materials with excess reactive molecules
CN104508675A (en) * 2012-05-30 2015-04-08 斯科特·麦克纳尔蒂 System, method and apparatus for electromagnetic detection and analysis of biometric information
US20170232246A1 (en) * 2014-11-07 2017-08-17 Toppan Printing Co., Ltd. Needle assembly for transdermal administration and method of producing the same
US10799691B2 (en) * 2014-11-07 2020-10-13 Toppan Printing Co., Ltd. Needle assembly for transdermal administration and method of producing the same
WO2018080923A1 (en) * 2016-10-28 2018-05-03 Georgetown University Non-invasive passive interstitial fluid collector
US11534090B2 (en) 2016-10-28 2022-12-27 Georgetown University Non-invasive passive interstitial fluid collector
US11247206B2 (en) 2017-01-31 2022-02-15 Georgetown University Harvesting cell-free non-coding RNAS (CFNCRS) from interstitial fluid for sensitive biomarkers

Also Published As

Publication number Publication date
WO1998000193A1 (en) 1998-01-08
DE69722414T2 (en) 2004-05-19
US6183434B1 (en) 2001-02-06
CA2259437A1 (en) 1998-01-08
EP0921840A1 (en) 1999-06-16
EP0921840A4 (en) 2000-04-12
CA2259437C (en) 2006-12-05
DE69722414D1 (en) 2003-07-03
ES2200187T3 (en) 2004-03-01
JP3942640B2 (en) 2007-07-11
ATE241405T1 (en) 2003-06-15
AU3880697A (en) 1998-01-21
JP2000513971A (en) 2000-10-24
EP0921840B1 (en) 2003-05-28
DK0921840T3 (en) 2003-09-22

Similar Documents

Publication Publication Date Title
US6183434B1 (en) Multiple mechanical microporation of skin or mucosa
US8172815B2 (en) Device for withdrawing or administrating a substance and method of a device
Gardeniers et al. Silicon micromachined hollow microneedles for transdermal liquid transport
JP4668535B2 (en) A device that supplies or withdraws substances through the skin of animals
DE69937338T2 (en) INTEGRATED TISSUE PORATION, LIQUID COLLECTION AND ANALYSIS DEVICE
EP1652551B1 (en) Microneedle arrays
AU2007202052B2 (en) Microneedle devices and production thereof
US7344499B1 (en) Microneedle device for extraction and sensing of bodily fluids
JP4892166B2 (en) Micro device and method for manufacturing the same
US5879326A (en) Method and apparatus for disruption of the epidermis
US9717451B2 (en) Device for withdrawing or administering a substance and method of manufacturing a device
JP2007325955A (en) System for delivery of drug by transport
US20080058726A1 (en) Methods and Apparatus Incorporating a Surface Penetration Device
JP2003534881A (en) Method and apparatus for enhancing penetration of a piercing member into an intradermal space
JP2004505652A (en) Apparatus for microporation of biological membranes using thin-film tissue interface devices and methods therefor
Zahn Microfabricated microneedles for minimally invasive drug delivery, sampling and analysis
Zhang et al. Micromachined needles for microbiological sample and drug delivery system
Tan et al. Novel low-cost fabrication of microneedle arrays for drug delivery applications
Griss Micromachined interfaces for medical and biochemical applications
AU2002253812A1 (en) Microneedle devices and production thereof

Legal Events

Date Code Title Description
STCB Information on status: application discontinuation

Free format text: ABANDONED -- FAILURE TO RESPOND TO AN OFFICE ACTION

AS Assignment

Owner name: ALTEA THERAPEUTICS CORPORATION, GEORGIA

Free format text: CHANGE OF NAME;ASSIGNOR:ALTEA DEVELOPMENT CORP.;REEL/FRAME:013295/0519

Effective date: 20021120

Owner name: ALTEA DEVELOPMENT CORP., GEORGIA

Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNOR:ALTEA TECHNOLOGIES, INC.;REEL/FRAME:013295/0426

Effective date: 20021107

AS Assignment

Owner name: ALTEA DEVELOPMENT CORP., GEORGIA

Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNOR:ALTEA TECHNOLOGIES, INC.;REEL/FRAME:013699/0145

Effective date: 20021107

AS Assignment

Owner name: ALTEA THERAPEUTICS CORPORATION, GEORGIA

Free format text: CHANGE OF NAME;ASSIGNOR:ALTEA DEVELOPMENT CORP.;REEL/FRAME:013699/0641

Effective date: 20021108

AS Assignment

Owner name: ALTEA DEVELOPMENT CORP., GEORGIA

Free format text: CHANGE OF NAME;ASSIGNOR:ALTEA TECHNOLOGIES, INC.;REEL/FRAME:013746/0511

Effective date: 20030108